Takeda Reports Positive Phase 3 Results for Psoriasis Treatment Zasocitinib
Takeda has announced positive Phase 3 data for its daily oral psoriasis treatment, zasocitinib. The company is now planning an FDA filing as it faces a high-stakes competitive landscape against established market leaders.